pipeline-prospector-insert-v1
X

Find Gastroenterology Drugs in Phase II/III Clinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Brazikumab

            Therapeutic Area: Gastroenterology

            Highest Development Status: Phase II/ Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: AstraZeneca

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Divestment January 27, 2020

            Details:

            AstraZeneca will acquire brazikumab, in Phase 2b/3 development for Crohn's Disease and in Phase 2 development for ulcerative colitis, including global development and commercial rights.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Galacto-oligosaccharide

            Therapeutic Area: Gastroenterology

            Highest Development Status: Phase II/ Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Qualigen

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Merger January 21, 2020

            Details:

            The merged company will focus on the development of Qualigen’s nanotechnology therapies for the treatment of cancer and infectious diseases, while also continuing to operate its profitable diagnostic business.